CA2319057A1 - Compositions comprising a poly(oxyethylene)-poly(oxypropylene) block copolymer and their use - Google Patents

Compositions comprising a poly(oxyethylene)-poly(oxypropylene) block copolymer and their use Download PDF

Info

Publication number
CA2319057A1
CA2319057A1 CA002319057A CA2319057A CA2319057A1 CA 2319057 A1 CA2319057 A1 CA 2319057A1 CA 002319057 A CA002319057 A CA 002319057A CA 2319057 A CA2319057 A CA 2319057A CA 2319057 A1 CA2319057 A1 CA 2319057A1
Authority
CA
Canada
Prior art keywords
block copolymer
derivative
poly
ethylene
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002319057A
Other languages
French (fr)
Other versions
CA2319057C (en
Inventor
Alexander V. Kabanov
Valery Y. Alakhov
Elena V. Batrakova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supratek Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2319057A1 publication Critical patent/CA2319057A1/en
Application granted granted Critical
Publication of CA2319057C publication Critical patent/CA2319057C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

This invention relates to a copolymer pharmaceutical composition useful in oral administration of a number of biological agents or protein, peptide, or derivatives thereof, and a poly(oxyethylene)-poly(oxypropylene) block copolymer. The composition for the delivery of biologically active agents comprises a mixture of poly(oxyethene)--poly(oxypropylene) block copolymers and at least one biologically active agent, wherein the mixture comprises at least one block copolymer with ethylene oxide content of less than 50% and at least one block copolymer with ethylene oxide content of more than 50%. The compositions are useful in the oral delivery of numerous agents and are particularly effective in the delivery of biologically active agents and in reversing resistance to a biological agent.

Claims (21)

1. A composition for the delivery of biologically active agents comprising a poly(oxyethylene)-poly(oxypropylene) block copolymer and at least one of the following:
(a) at least one protein, peptide, or derivative thereof, (b) at least one biologically active agent, or derivative thereof having reduced cellular transport, reduced penetration into tissues, or reduced penetration across biological burners, due to membrane proteins, and wherein the hydrophobe percentage of the poly(oxyethylene)-poly(oxypropylene) block copolymer is at least about 50%.
2. The composition according to claim 1, wherein said block copolymer is of the formula:

in which x, y, z, i, and j have values from about 2 to about 800, and wherein for each R1, R2 pair, one is hydrogen and the other is a methyl group.
3. A composition for the delivery of a biologically active agent, or derivative thereof, comprising a biologically active agent, or derivative thereof, and a poly(oxyethylene)-poly(oxypropylene) block copolymer of the formula:

wherein for each R1, R2 pair, one is hydrogen and the other is a methyl group.
4. A composition for the delivery of a biologically active agent, or derivative thereof comprising a biologically active agent, or derivative thereof, and a poly(oxyethylene)-poly(oxypropylene) block copolymer of the formula:

in which x, y, and z have values from about 2 to about 800.
5. A composition comprising at least one block copolymer with ethylene(oxide) content of 50% or less, and at least one block copolymer with ethylene(oxide) content of 50% or more, and a biologically active agent.
6. The composition according to claim 5, wherein the ratio by weight of the block copolymer with ethylene(oxide) content of 50% or less to the block copolymer with ethylene(oxide) content of 50% or more is 1:2.
7. The composition according to claim 5, wherein the ratio by weight of the block copolymer with ethylene(oxide) content of 50% or less to the block copolymer with ethylene(oxide) content of 50% or more is 1:5.
8. The composition according to claim 1, wherein the protein. peptide or derivative thereof is selected from the group consisting of immunomodulators, cytokines, hormones, enzymes, tissue plasminogen activators, clotting factors, colony stimulating factors, and erythropoietins.
9. The composition according to claim 8 wherein the hormone is a human growth hormone.
10. The composition according to claim 9 wherein the hormone is insulin.
11. The composition according to claim 1 wherein the protein, peptide, or derivative thereof is a neuropeptide, or derivative thereof.
12. The composition according to claim 1 wherein the protein, peptide, or derivative thereof is selected from the group consisting of recombinant soluble receptors and monoclonal antibodies.
13. A method of treating a mammal comprising administering to said mammal an effective amount of a composition according to claim 1.
14. The method according to claim 13, wherein said block copolymer is of the formula:

in which x, y, z, i, and j have values from about 2 to about 800, and wherein for each R1, R2 pair, one is hydrogen and the other is a methyl group.
15. The method according to claim 13 wherein said block copolymer is of the formula:

wherein for each R1, R2 pair, one is hydrogen and the other is a methyl group, and the ethylene(oxide) content of said block copolymer is less than 50%.
16. The method according to claim 13 further comprising at least one block copolymer with ethylene(oxide) content of less than 50%, and at least one block copolymer with ethylene(oxide) content of more than 50%.
17. The method according to claim 13, wherein the protein, peptide or derivative thereof is selected from the group consisting of immunomodulators, cytokines, hormones, enzymes, tissue plasminogen activators, clotting factors, colony stimulating factors, and erythropoietins.
18. The method according to claim 17 wherein the hormone is a human growth hormone.
19. The method according to claim 18 wherein the hormone is insulin.
20. The method according to claim 13 wherein the protein, peptide, or derivative thereof is a neuropeptide, or derivative thereof.
21. The method according to claim 13 wherein the protein, peptide, or derivative thereof is selected from the group consisting of recombinant soluble receptors and monoclonal antibodies.
CA2319057A 1998-02-06 1999-02-05 Compositions comprising a poly(oxyethylene)-poly(oxypropylene) block copolymer and their use Expired - Fee Related CA2319057C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/019,648 US6277410B1 (en) 1992-10-08 1998-02-06 Copolymer compositions for oral delivery
US09/019,648 1998-02-06
PCT/US1999/002538 WO1999039731A1 (en) 1998-02-06 1999-02-05 Copolymer compositions for oral delivery

Publications (2)

Publication Number Publication Date
CA2319057A1 true CA2319057A1 (en) 1999-08-12
CA2319057C CA2319057C (en) 2010-05-04

Family

ID=21794304

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2319057A Expired - Fee Related CA2319057C (en) 1998-02-06 1999-02-05 Compositions comprising a poly(oxyethylene)-poly(oxypropylene) block copolymer and their use

Country Status (8)

Country Link
US (2) US6277410B1 (en)
EP (1) EP1053010B1 (en)
JP (1) JP4685237B2 (en)
AT (1) ATE426397T1 (en)
AU (1) AU2496199A (en)
CA (1) CA2319057C (en)
DE (1) DE69940635D1 (en)
WO (1) WO1999039731A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
EP1563850A3 (en) * 2000-02-23 2008-02-20 Pfizer Products Inc. Method of increasing the bioavailability and tissue penetration of azithromycin
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
EP1283727A4 (en) * 2000-04-28 2007-10-10 Supratek Pharma Inc Compositions and methods for inducing activation of dendritic cells
EP1289542B1 (en) * 2000-05-26 2008-07-16 Frohwitter, Bernhard Means for maintenance and/or correction of glucose concentration in blood
US6861431B2 (en) 2001-03-23 2005-03-01 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
GB0131112D0 (en) * 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers
JP2005538191A (en) * 2002-07-29 2005-12-15 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド Aqueous 2,6-diisopropylphenol pharmaceutical composition
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
US7429382B2 (en) 2002-10-16 2008-09-30 Corixa Corporation Antibodies that bind cell-associated CA 125/O772P and methods of use thereof
US7422875B2 (en) 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
JP2009523130A (en) * 2006-01-10 2009-06-18 イノバフォーム テクノロジーズ エルエルシー Insecticide delivery system
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
RU2409363C9 (en) * 2009-09-18 2013-12-10 Всеволод Иванович Киселев Pharmaceutical compositions for peroral delivery of diindolylmethane (dim) and methods for application of these compositions
US8946301B2 (en) 2011-11-29 2015-02-03 Als Therapy Development Institute Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027013A (en) 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4106474A (en) 1977-03-17 1978-08-15 Modine Manufacturing Company Heat conserving space heater
US4865835A (en) 1982-06-02 1989-09-12 Begent Richard H J Diagnosis and treatment of tumors
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
CA1224148A (en) * 1983-05-16 1987-07-14 John L. Haslam Drug delivery system utilizing thermosetting gels
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4485457A (en) 1983-05-31 1984-11-27 Cbs Inc. Memory system including RAM and page switchable ROM
US4772466A (en) 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
JPS61103836A (en) 1984-10-24 1986-05-22 Green Cross Corp:The Fibronectin pharmaceutical preparation
US5466445A (en) 1985-06-18 1995-11-14 Emory University Methods for reducing salmonella in chickens
US5114708A (en) 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US5494660A (en) 1985-06-18 1996-02-27 Emory University Method for inhibiting microbial binding to surfaces
ATE73338T1 (en) * 1985-06-18 1992-03-15 Univ Emory BIOLOGICALLY ACTIVE COPOLYMERS.
US5183687A (en) 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US5234683A (en) 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
BR8603586A (en) 1985-07-30 1987-03-10 Int Minerals & Chem Corp PROCESS TO MAINTAIN THE FLUIDITY OF A HOMONIUM; PROCESS TO PERFORM GROWTH PROMOTION IN ANIMALS AND GROWTH PROMOTING FORMULATION
US5071649A (en) 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US4997644A (en) 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US4873083A (en) 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5152979A (en) 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5064643A (en) 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5250294A (en) 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5047236A (en) 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5080894A (en) 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5032394A (en) 1986-05-15 1991-07-16 Emory University Method of treating burns
US5089260A (en) 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US4937070A (en) 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5028599A (en) 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5240701A (en) 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US5041288A (en) 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US4837014A (en) 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5017370A (en) 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5039520A (en) 1986-05-15 1991-08-13 Emory University Plasma extender
US4801452A (en) 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5078995A (en) 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5198211A (en) 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5182106A (en) 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5240702A (en) 1986-05-15 1993-08-31 Emory University Method of treating stroke
US5030448A (en) 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US4897263A (en) 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4879109A (en) 1986-05-15 1989-11-07 Emory University Method for treating burns
US4882168A (en) 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
ATE108067T1 (en) * 1986-09-22 1994-07-15 Univ Emory VACCINE AND METHOD OF MANUFACTURE.
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US5567859A (en) * 1991-03-19 1996-10-22 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
ATE82129T1 (en) * 1987-02-20 1992-11-15 Univ Emory ANTI-INFECTIOUS COMPOUNDS AND METHODS OF USE.
EP0382736B1 (en) 1987-07-27 1994-11-02 Commonwealth Scientific And Industrial Research Organisation Receptor membranes
US4853228A (en) 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
BR9106377A (en) * 1990-04-26 1993-04-27 Cytrx Corp COMPOSITION AND PROCESS FOR TOPICAL TREATMENT OF INJURED OR NURSING TISSUE
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE69230372T2 (en) * 1991-03-19 2000-06-15 Cytrx Corp POLYOXYPROPYLEN / POLYOXYETHYLEN COPOLYMERE WITH IMPROVED BIOLOGICAL ACTIVITY
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
ATE182278T1 (en) 1991-10-04 1999-08-15 Gs Dev Ab PARTICLES, METHOD FOR PRODUCING THE PARTICLES AND THEIR USE
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5470568A (en) 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
KR940003548U (en) 1992-08-14 1994-02-21 김형술 Laundry dryer
US6153193A (en) 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
EP0619730B1 (en) 1992-10-08 2000-12-27 Supratek Pharma Inc. Composition of antineoplastic agents incorporated in micelles
US5840319A (en) 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
CA2155005C (en) 1993-02-02 1999-04-06 Weldon Courtney Mcgregor Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
IL106578A (en) 1993-08-03 2000-08-13 Yissum Res Dev Co Pharmaceutical compositions for drug targeting
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5401296A (en) 1994-06-28 1995-03-28 Martenson; Irvin Precious metal extraction process
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
JP4117922B2 (en) * 1996-03-28 2008-07-16 武田薬品工業株式会社 Sustained release preparation and production method thereof

Also Published As

Publication number Publication date
WO1999039731A1 (en) 1999-08-12
EP1053010A4 (en) 2002-08-21
EP1053010B1 (en) 2009-03-25
ATE426397T1 (en) 2009-04-15
JP4685237B2 (en) 2011-05-18
US6387406B1 (en) 2002-05-14
AU2496199A (en) 1999-08-23
EP1053010A1 (en) 2000-11-22
JP2002502825A (en) 2002-01-29
DE69940635D1 (en) 2009-05-07
US6277410B1 (en) 2001-08-21
CA2319057C (en) 2010-05-04

Similar Documents

Publication Publication Date Title
CA2319057A1 (en) Compositions comprising a poly(oxyethylene)-poly(oxypropylene) block copolymer and their use
US5098702A (en) Combination therapy using interleukin-2 and tumor necrosis factor
Roberts et al. Multiple forms of TGF‐β: distinct promoters and differential expression
JP2002502825A5 (en)
Clevenger et al. Interleukin-2 driven nuclear translocation of prolactin in cloned T-lymphocytes
CA2664318C (en) Long lasting drug formulations
CZ247194A3 (en) Conventional leukocytic interferon, its use for preparing a medicament and a pharmaceutical preparation based thereon
WO1990007923A1 (en) Transmembrane formulations for drug administration
CN101351219A (en) Stable formulations containing enhancing proportions of gamma- and alpha-interferons
CA2340728C (en) Methods of treating hypertension and compositions for use therein
US9127084B2 (en) Long lasting drug formulations
Kilian et al. Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH: OVCAR-3)
Tamada et al. The effects of heparin-binding epidermal growth factor-like growth factor on preimplantation-embryo development and implantation in the rat
EP1066059B1 (en) Formulations for protection of peg-interferon alpha conjugates
US6719977B1 (en) Methods to potentiate cancer therapies
AU768986B2 (en) IL-6/sIL-6R complex for promotion of liver functions
JPH09503788A (en) Therapeutic delivery compositions and methods of use thereof
Fujioka et al. Long-acting delivery system of interferon: IFN minipellet
CA1290249C (en) COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
EP0549702B1 (en) Use of recombinant colony stimulating factor-1
CA2464529A1 (en) Method of treating estrogen responsive breast cancer
US20130171107A1 (en) Long lasting drug formulations
Sekyi-Otu et al. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement
Bernstein et al. A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia
Van Gils et al. Acute side effects of homologous interleukin-3 in rhesus monkeys.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150205